

Boston-based Decibel Therapeutics, a developer of novel restorative gene therapeutics to treat hearing loss and balance disorders, has raised $82.2 million in Series D financing. OrbiMed led the round.
Source: Press Release
Boston-based Decibel Therapeutics, a developer of novel restorative gene therapeutics to treat hearing loss and balance disorders, has raised $82.2 million in Series D financing.
Boston-based Decibel Therapeutics, a developer of novel restorative gene therapeutics to treat hearing loss and balance disorders, has raised $82.2 million in Series D financing. OrbiMed led the round.
Source: Press Release
Copyright PEI Media
Not for publication, email or dissemination